78686-86-9

Basic information

• Product Name: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE
• Synonyms: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE;3-Pyridinecarbonyl chloride, 5-bromo-2-chloro-
• CAS NO: 78686-86-9
• Molecular Formula: C₆H₂BrCl₂NO
• Molecular Weight: 254.89618
• Mol File: 78686-86-9.mol

Chemical Properties

• Boiling Point: 297.008 °C at 760 mmHg
• Flash Point: 133.426 °C
• Appearance: /
• Density: 1.858 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE(78686-86-9)
• EPA Substance Registry System: 5-BROMO-2-CHLORO-3-PYRIDINECARBONYL CHLORIDE(78686-86-9)

Safety Data

• Hazardous Substances Data: 78686-86-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Manufacturing:
5-Bromo-2-chloro-3-pyridinecarbonyl chloride is used as a derivatization agent for the synthesis of a variety of pharmaceuticals. Its unique structure and reactivity enable the modification of target compounds, enhancing their properties and therapeutic effects.
Used in Chemical Synthesis:
In the chemical industry, 5-Bromo-2-chloro-3-pyridinecarbonyl chloride serves as a key intermediate in the synthesis of various organic compounds. Its versatility and reactivity make it a valuable component in the development of new chemical entities with diverse applications.
Used in Research and Development:
5-Bromo-2-chloro-3-pyridinecarbonyl chloride is utilized in research and development laboratories for the exploration of new chemical reactions and the synthesis of novel compounds. Its unique properties and reactivity contribute to the advancement of scientific knowledge and the discovery of innovative materials and pharmaceuticals.
Used in Analytical Chemistry:
As a halogenated carbonyl compound, 5-Bromo-2-chloro-3-pyridinecarbonyl chloride is employed in analytical chemistry for the derivatization of analytes, improving their detection and analysis in various techniques such as chromatography and mass spectrometry.
Used in Material Science:
5-Bromo-2-chloro-3-pyridinecarbonyl chloride is also used in material science for the synthesis of functional materials with specific properties. Its incorporation into polymers, for example, can enhance their performance in various applications, such as sensors, catalysts, or advanced materials for energy storage and conversion.

InChI:InChI=1/C6H2BrCl2NO/c7-3-1-4(6(9)11)5(8)10-2-3/h1-2H

Upstream product

• 52833-94-0 2-amino-5-bromonicotinicacid 
• 104612-36-4 5-bromo-2-hydroxynicotinic acid 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 2942-59-8 2-chloronicotinic acid 
• 931105-54-3 Sodium 5-bromo-2-chloronicotinate 
• 32282-06-7 3-amino-2-(ethylamino)pyridine 
• 29241-65-4 5-bromo-2-chloronicotinic acid 

Downstream Products

• 211750-50-4 BIRK 122 
• 134698-42-3 5,11-dihydro-11-ethyl-8-bromo-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one 
• 162109-00-4 2-bromo-5-ethyl-10-methyl-5,10-dihydro-4,5,6,10-tetraazadibenzo[a,d]cyclohepten-11-one 
• 1289189-96-3 C₇H₇BrN₄ 
• 1188142-86-0 5-bromo-2-chloro-N,N-dimethylpyridine-3-carboxamide 
• 78686-79-0 methyl 2-chloro-5-bromonicotinate 
• 1189749-84-5 C₇H₆BrClN₂O 
• 952152-79-3 (S)-N-((3-(3,5-difluoro-4-(2-bromo-10-oxo-5,6,8,9-tetrahydro-10H-4,4b,7,9a-tetraazabenzo[a]azulen-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide 

Relevant articles and documents

Synthesis of [14C]- and [13C6]-labeled potent HIV non-nucleoside reverse transcriptase inhibitor

5,11-Dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl} -6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one, (1), labeled with carbon-14 in the quinoline-benzene ring, in one of the pyridine rings of the dipyridodiazepinone tricyclic moiety, and in the side chain, was prepared in three different syntheses with specific activities ranging from 44 to 47 mCi/mmol (1.63-1.75 GBq/mmol). In the first synthesis, 5,11-dihydro-11-ethyl-8- (2-hydroxyethyl)-5-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4] diazepin-6-one (2) was coupled to 4-hydroxyquinoline, [benzene- 14C(U)]-, using Mitsunobu's reaction conditions, followed by the oxidation of the quinoline nitrogen with 3-chloroperoxybenzoic acid to give ([14C]-(1a)) in 43% radiochemical yield. Second, 3-amino-2- chloropyridine, [2,6-14C]-, was used to prepare 8-bromo-5,11-dihydro- 11-ethyl-5-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one (8), and then Stille coupled to allyl(tributyl)tin followed by ozonolysis of the terminal double bond and in situ reduction of the resulting aldehyde to alcohol (10). Mitsunobu etherification and oxidation as seen before gave ([ 14C]-(1b)) in eight steps and in 11% radiochemical yield. Finally, carbon-14 potassium cyanide was used to prepare isopropyl cyanoacetate (12), which was used to transform bromide (8) to labeled aryl acetic acid (13) under palladium catalysis. Trihydroborane reduction of the acid gave alcohol (14) labeled in the side chain, which was used as described above to prepare ([ 14C]-(1c)) in 4.3% radiochemical yield. The radiochemical purities of these compounds were determined by radio-HPLC and radio-TLC to be more than 98%. To prepare [13C6]-(1), [13C 6]-4-hydroxyquinoline was prepared from [13C 6]-aniline and then coupled to (2) and oxidized as seen before. Copyright

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 (ALDH2) BINDING POLYCYCLIC AMIDES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention provides compounds of formula I that bind to mitochondrial aldehyde dehydrogenase-2 (ALDH2), and methods of using said compounds to treat patients with i.a. cancer, Fanconi anemia and alcohol-related disorders. [Formula should be ins

Iridium-catalyzed C-H borylation of heteroarenes: Scope, regioselectivity, application to late-stage functionalization, and mechanism

A study on the iridium-catalyzed C-H borylation of heteroarenes is reported. Several heteroarenes containing multiple heteroatoms were found to be amenable to C-H borylation catalyzed by the combination of an iridium(I) precursor and tetramethylphenanthroline. The investigations of the scope of the reaction led to the development of powerful rules for predicting the regioselectivity of borylation, foremost of which is that borylation occurs distal to nitrogen atoms. One-pot functionalizations are reported of the heteroaryl boronate esters formed in situ, demonstrating the usefulness of the reported methodology for the synthesis of complex heteroaryl structures. Application of this methodology to the synthesis and late-stage functionalization of biologically active compounds is also demonstrated. Mechanistic studies show that basic heteroarenes can bind to the catalyst and alter the resting state from the olefin-bound complex observed during arene borylation to a species containing a bound heteroarene, leading to catalyst deactivation. Studies on the origins of the observed regioselectivity show that borylation occurs distal to N-H bonds due to rapid N-H borylation, creating an unfavorable steric environment for borylation adjacent to these bonds. Computational studies and mechanistic studies show that the lack of observable borylation of C-H bonds adjacent to basic nitrogen is not the result of coordination to a bulky Lewis acid prior to C-H activation, but the combination of a higher-energy pathway for the borylation of these bonds relative to other C-H bonds and the instability of the products formed from borylation adjacent to basic nitrogen.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.

6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4- dihydroquinolines as HIV integrase inhibitors

SAR studies on the quinolone carboxylic acid class of HIV-1 integrase inhibitors focused on improving the metabolic stability and led to the discovery of 27 and 38.

Synthesis of [14C]- and [13C6]-labeled potent HIV non-nucleoside reverse transcriptase inhibitor

Compound 1 (Figure 1), labeled with carbon-14 in the quinoline-benzene ring, in one of the pyridine rings of the dipyridodiazepinone tricyclic moiety, and in the side chain, was prepared in three different syntheses with specific activities ranging from 4

SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL

In one aspect, the present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to method for their preparation.

Development of a pilot-plant process for a nevirapine analogue HIV NNRT inhibitor

The pilot-plant synthesis of nevirapine analogue 1 is described. The compound was prepared in eight steps from substituted pyridine raw materials and 4-hydroxyquinoline. The key transformation involves a novel one-pot conversion of an arylhalide to arylac

MET kinase inhibitors

The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.